Balzarotti, M., Magagnoli, M., Canales, M. Á., Corradini, P., Grande, C., Sancho, J., . . . Carlo-Stella, C. (2021). A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma. Invest New Drugs.
Citação norma ChicagoBalzarotti, Monica, et al. "A Phase Ib, Open-label, Dose-escalation Trial of the Anti-CD37 Monoclonal Antibody, BI 836826, in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/refractory Diffuse Large B-cell Lymphoma." Invest New Drugs 2021.
MLA CitationBalzarotti, Monica, et al. "A Phase Ib, Open-label, Dose-escalation Trial of the Anti-CD37 Monoclonal Antibody, BI 836826, in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/refractory Diffuse Large B-cell Lymphoma." Invest New Drugs 2021.